EGFR assays in lung cancer

被引:40
作者
Dacic, Sanja [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA
关键词
lung cancer; EGFR; mutational analysis; FISH;
D O I
10.1097/PAP.0b013e31817bf5a9
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The development of small-molecule inhibitors of the epidermal growth factor receptor (EGFR) resulted in new therapeutic options for patients with advanced lung cancer. It was clear from the experience with targeted therapy for breast cancer that a new standardized assay procedure for assessing and predicting the effects of therapeutic agents must be developed. Three academic groups almost simultaneously reported the discovery of somatic mutations in the exons 18 to 21 of the tyrosine kinase (TK) domain of EGFR that correlated with a high likelihood of response to EGFR TK inhibitors. This observation revolutionized understanding of EGFR in lung carcinogenesis and resulted in numerous retrospective studies that correlated patient's response and molecular profile of the lung adenocarcinoma. The results of these studies indicate that clinical benefits from treatment with EGFR TK inhibitors are variable between the different subsets of patients. Multiple methodologic approaches were used including mutational analysis, fluorescence in situ hybridization, and immunohistochemistry. Conflicting results reflect the lack of standardization of the methodology and interpretation. Sample types, sample processing, and storage should also be taken into consideration as another potentially confounding factor. Therefore, it is important to standardize the approach and decide which assays are best to predict patient response to targeted therapies. It is also essential to determine the most cost-effective way to integrate EGFR molecular assays into clinical practice. This review will address practical aspects of each of the currently proposed assays. Difficulties in standardization of these assays in a clinical practice will be discussed.
引用
收藏
页码:241 / 247
页数:7
相关论文
共 62 条
[41]   EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].
Paez, JG ;
Jänne, PA ;
Lee, JC ;
Tracy, S ;
Greulich, H ;
Gabriel, S ;
Herman, P ;
Kaye, FJ ;
Lindeman, N ;
Boggon, TJ ;
Naoki, K ;
Sasaki, H ;
Fujii, Y ;
Eck, MJ ;
Sellers, WR ;
Johnson, BE ;
Meyerson, M .
SCIENCE, 2004, 304 (5676) :1497-1500
[42]   Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas [J].
Pan, QL ;
Pao, W ;
Ladanyi, M .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2005, 7 (03) :396-403
[43]   EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J].
Pao, W ;
Miller, V ;
Zakowski, M ;
Doherty, J ;
Politi, K ;
Sarkaria, I ;
Singh, B ;
Heelan, R ;
Rusch, V ;
Fulton, L ;
Mardis, E ;
Kupfer, D ;
Wilson, R ;
Kris, M ;
Varmus, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13306-13311
[44]   Epidermal growth factor receptor mutation testing in lung cancer: Searching for the ideal method [J].
Pao, William ;
Laclanyi, Marc .
CLINICAL CANCER RESEARCH, 2007, 13 (17) :4954-4955
[45]   Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer;: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization [J].
Ruiz, M. I. Gallegos ;
Floor, K. ;
Vos, W. ;
Grunberg, K. ;
Meijer, G. A. ;
Rodriguez, J. A. ;
Giaccone, G. .
HISTOPATHOLOGY, 2007, 51 (05) :631-637
[46]   Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer [J].
Sasaki, Hidefumi ;
Endo, Katsuhiko ;
Okuda, Katsuhiro ;
Kawano, Osamu ;
Kitahara, Naoto ;
Tanaka, Hisaichi ;
Matsumura, Akihide ;
Iuchi, Keiji ;
Takada, Minoru ;
Kawahara, Masaaki ;
Kawaguchi, Tomoya ;
Yukiue, Haruhiro ;
Yokoyama, Tomoki ;
Yano, Motoki ;
Fujii, Yoshitaka .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (05) :569-577
[47]   Epidermal growth factor receptor mutation testing in the care of lung cancer patients [J].
Sequist, Lecia V. ;
Joshi, Victoria A. ;
Jaenne, Pasi A. ;
Bell, Daphne W. ;
Fidias, Pahos ;
Lindeman, Neal I. ;
Louis, David N. ;
Lee, Jeffrey C. ;
Mark, Eugene J. ;
Longtine, Janina ;
Verlander, Peter ;
Kucherlapati, Raju ;
Meyerson, Matthew ;
Haber, Daniel A. ;
Johnson, Bruce E. ;
Lynch, Thomas J. .
CLINICAL CANCER RESEARCH, 2006, 12 (14) :4403S-4408S
[48]   Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers [J].
Shigematsu, H ;
Gazdar, AF .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (02) :257-262
[49]   Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer [J].
Shih, JY ;
Gow, CH ;
Yu, CJ ;
Yang, CH ;
Chang, YL ;
Tsai, MF ;
Hsu, YC ;
Chen, KY ;
Su, WP ;
Yang, PC .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (04) :963-969
[50]   EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer [J].
Shih, JY ;
Gow, CH ;
Yang, PC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :207-208